Development of Shared Resources

7.5.4.1描述和使命 有几种方法可以优化新的癌症治疗方法。药物调度和药代动力学 问题显然与结果有关。例如，* 剂量密集计划在乳腺癌中提供了上级结局 癌症辅助治疗。药物代谢和药物水平不足，如他莫昔芬， 也可能对结果产生不利影响。 了解和识别对抗癌药物治疗反应性的变异性来源是一个 这对临床研究者来说是一个巨大的挑战。可变性的来源可能不明显，因此， 需要有助于识别、解释和评估变异性的技术，以确保正确解释 临床试验结果。正在开发的临床药理学共享资源将提供给癌症中心 成员： 咨询服务，以协助设计，执行和数据解释的药代动力学， 药效学和药物遗传学研究 * 药物分析和药物定量研究样本开发的分析服务， 提供样本采集服务，协助获取、处理和储存样本， 多中心药理学研究。

7.5.4.1 DESCRIPTION AND MISSION There are several ways that new cancer therapeutics can be optimized. Drug scheduling and pharmacokinetic issues clearly relate to outcome. For example* dose-dense scheduling provides superior outcomes in breast cancer adjuvant therapy. Drug metabolism and inadequate drug levels, as has been suggested for tamoxifen, may also adversely affect outcome. Understanding and identifying sources of variability in responsiveness to anti-cancer drug therapy is a significant challenge to clinical investigators. The source of variability may not be obvious and thus, techniques to help identify, explain and evaluate the variability are needed to assure proper interpretation of clinical trial results. The developing Clihical Pharmacology Shared Resource will provide to Cancer Center members: ¿ consultion services to assist in the design, conduct and data interpretation of pharmacokinetic, pharmacodynamic and pharmacogenetjc studies* ¿ analytical services for development of drug assays and drug quantification of study specimens, ¿ sample acquisition services to assist in obtaining, processing and storage of samples for local and multi-center pharmacology studies.